Editas Medicine (EDIT) Shares Outstanding (Weighted Average) (2015 - 2025)

Editas Medicine (EDIT) has 11 years of Shares Outstanding (Weighted Average) data on file, last reported at $97.9 million in Q4 2025.

• Shares Outstanding (Weighted Average) for Q4 2025 came in at $97.9 million, up 18.86% year-over-year; the trailing twelve-month figure through Dec 2025 was $97.9 million (up 18.86% YoY), and the FY2025 annual result was $97.9 million, up 18.86% from the prior year.
• Shares Outstanding (Weighted Average) climbed to $97.9 million in Q4 2025 per EDIT's latest filing, from $90.1 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $97.9 million in Q4 2025 and troughed at $66.0 million in Q1 2021.
• A 5-year average of $75.8 million and a median of $72.1 million in 2023 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2021 and 2022: Shares Outstanding (Weighted Average) advanced 21.78% in 2021, then increased 0.59% in 2022.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $67.6 million in 2021, then grew by 1.55% to $68.7 million in 2022, then grew by 10.63% to $76.0 million in 2023, then gained by 8.39% to $82.3 million in 2024, then gained by 18.86% to $97.9 million in 2025.
• Business Quant data shows EDIT's Shares Outstanding (Weighted Average) at $97.9 million in Q4 2025, $90.1 million in Q3 2025, and $84.4 million in Q2 2025.